問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Pediatrics

更新時間:2023-09-19

曾敏華Tseng, Min-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years
  • doc31089@cgmh.org.tw

篩選

List

10Cases

2022-04-01 - 2025-09-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2023-12-13 - 2027-03-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-12-01 - 2029-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-02-01 - 2029-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-15 - 2029-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-11-21 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2023-12-01 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2025-05-01 - 2027-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2017-09-01 - 2022-12-20

Phase III

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)
  • Condition/Disease

    Atypical Hemolytic Uremic Syndrome (aHUS)

  • Test Drug

    ALXN1210

Participate Sites
3Sites

Terminated3Sites

2017-07-01 - 2020-02-16

Phase III

Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
  • Condition/Disease

    Atypical Hemolytic Uremic Syndrome (aHUS)

  • Test Drug

    ALXN1210

Participate Sites
4Sites

Terminated4Sites